Title
Silymarin in NAFLD
Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters
Phase
Phase 4Lead Sponsor
University Hospital, RijekaStudy Type
InterventionalStatus
WithdrawnIndication/Condition
Non-Alcoholic Fatty Liver DiseaseIntervention/Treatment
silymarin ...Study Participants
0This study evaluates the influence of Silymarin in reducing laboratory, ultrasonographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive Silymarin (Verum) while the other half will receive placebo
In this study will participate patients who come to the regular ambulatory examinations (referred by gastroenterologists, nephrologists or family physicians in the Department of Gastroenterology and Department of Nephrology, dialysis and kidney transplantation KBC Rijeka) and have one or more components of the metabolic syndrome (hypertension, diabetes, obesity, dyslipidemia).Nonalcoholic fatty liver disease will be defined by transient elastography (FibroScan, Echosens, Paris); Controlled Attenuation Parameter (CAP) for assesment of liver steatosis and Liver Stiffness Measurements (LSM) for liver fibrosis. In all patients other causes of chronic liver disease will be excluded; chronic viral hepatitis, autoimmune diseases and other metabolic liver diseases as well as use of drugs than can cause liver steatosis and fibrosis and alcoholic liver disease.
This study will include 350 patients. Taking into account the possible drop-out rate around 15% of the patients during the study period, a total of 400 patients will be randomized. Patients will be randomized into two groups. The first group will be consisted of the patients with NAFLD who will be receiving Verum therapy during the 6 month period. The second group will be consisted of the patients with NAFLD who will be receiving placebo during the 6 months period, which will be identical to the Verum preparation in its packaging and form.
After the 6 months of therapy in all patients will be evaluated: liver enzymes and metabolic laboratory parameters of NAFLD (insulin resistance, lipidogram and serum glucose), as well as the TE-CAP in order to evaluate the efficiency of Silymarin for the treatment of NAFLD.
Capsules contains 100 mg of silymarin
Capsule will be identical in shape, size and color, packed in the same way like verum
Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
Inclusion Criteria: NAFLD patients signed informed consent possibility to follow instruction and the protocol Exclusion Criteria: chronic B or C hepatitis usage of hepatotoxic drugs in the period of 6 months before inclusion chronic kidney insufficiency (grade 4 and 5), hemodialysis any other chronic liver disease opioid dependancy any malignancy HIV seropositivity alcohol abuse pregnancy inability to follow the protocol